Back to Clinical Trials
Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Sponsored by Hoffmann-La Roche

About this study

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.

Where this study is enrolling (3)

Who can participate

Inclusion criteria

  • ✓Body weight within 40-110 kilograms (kg) (88-242 pounds \[lbs\]) and a body mass index within the range 18-34 kg/m2
  • ✓Diagnosis of idiopathic PD based on Movement Disorder Society (MDS) criteria
  • ✓Has received monotherapy treatment
  • ✓An MDS-UPDRS Part IV score of 0 at screening and prior to randomization
  • ✓Hoehn and Yahr (H\&Y) Stage 1 or 2 off medication at screening and prior to randomization
  • ✓Agreement to adhere to the contraception requirements

Exclusion criteria

  • ✕Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which contraception is required
  • ✕Medical history indicating a parkinsonian syndrome other than idiopathic PD
  • ✕Diagnosis of a significant neurologic disease other than PD
  • ✕Chronic uncontrolled hypertension

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.